• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

米库氯铵(BW B1090U)在接受氧化亚氮-阿片类-巴比妥类麻醉患者中的心血管效应。

The cardiovascular effects of mivacurium chloride (BW B1090U) in patients receiving nitrous oxide-opiate-barbiturate anesthesia.

作者信息

Savarese J J, Ali H H, Basta S J, Scott R P, Embree P B, Wastila W B, Abou-Donia M M, Gelb C

机构信息

Harvard Medical School, Massachusetts General Hospital, Boston 02114.

出版信息

Anesthesiology. 1989 Mar;70(3):386-94. doi: 10.1097/00000542-198903000-00003.

DOI:10.1097/00000542-198903000-00003
PMID:2564261
Abstract

The dose-effect relationship of mivacurium chloride on arterial blood pressure, heart rate, and plasma histamine was determined in 97 consenting ASA physical status I-II patients receiving nitrous oxide-oxygen-opiate-barbiturate anesthesia. In the absence of surgical stimulation during steady state anesthetic conditions with controlled ventilation, average maximum change in tachograph-counted heart rate was 7% or less after 10-15-s injection of mivacurium at all doses from 0.03 to 0.30 mg/kg. Average peak change in mean arterial pressure measured via radial arterial catheter was 7% or less after all doses from 0.03 to 0.15 mg/kg. Transient (0.2-4.5 min) decreases in arterial blood pressure were noted after 10-15-s injection in some patients at 0.20, 0.25, and 0.30 mg/kg. When they occurred, these changes were usually accompanied by facial erythema lasting 2-5 min and were correlated with increases in plasma histamine level (P less than 0.001). Facial erythema, decrease in blood pressure, and elevation of histamine level were all accentuated by increasing the dose of mivacurium and by more rapid injection of the drug. For example, mean blood pressure decreased an average of 13% after injection of mivacurium 0.25 mg/kg over 10-15 s. In contrast, during administration over 30 and 60 s of this dose, arterial pressure decreased 7.6 and 1.5%, respectively (P less than 0.001, 10-15 s vs. 60-s injection). Average peak histamine level, which increased to 132% of control after administration of 0.25 mg/kg over 10-15 s, did not change after injection over 60 s.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

在97例接受氧化亚氮-氧气-阿片类-巴比妥类麻醉且自愿参与的美国麻醉医师协会(ASA)身体状况I-II级患者中,测定了氯化米库氯铵对动脉血压、心率和血浆组胺的剂量-效应关系。在稳定麻醉状态且控制通气、无手术刺激的情况下,在0.03至0.30mg/kg的所有剂量下,经10 - 15秒注射氯化米库氯铵后,由转速记录仪记录的平均最大心率变化在7%或更低。经桡动脉导管测量,在0.03至0.15mg/kg的所有剂量后,平均动脉压的平均峰值变化在7%或更低。在一些接受0.20、0.25和0.30mg/kg剂量的患者中,经10 - 15秒注射后,观察到动脉血压出现短暂(0.2 - 4.5分钟)下降。当出现这种情况时,这些变化通常伴有持续2 - 5分钟的面部红斑,且与血浆组胺水平升高相关(P小于0.001)。面部红斑、血压下降和组胺水平升高均因增加氯化米库氯铵剂量和更快注射药物而加剧。例如,在10 - 15秒内注射0.25mg/kg氯化米库氯铵后,平均血压平均下降13%。相比之下,在30秒和60秒内给予该剂量时,动脉压分别下降7.6%和1.5%(P小于0.001,10 - 15秒注射与60秒注射相比)。在10 - 15秒内给予0.25mg/kg后,平均组胺峰值水平增加至对照值的132%,在60秒注射后未发生变化。(摘要截断于250字)

相似文献

1
The cardiovascular effects of mivacurium chloride (BW B1090U) in patients receiving nitrous oxide-opiate-barbiturate anesthesia.米库氯铵(BW B1090U)在接受氧化亚氮-阿片类-巴比妥类麻醉患者中的心血管效应。
Anesthesiology. 1989 Mar;70(3):386-94. doi: 10.1097/00000542-198903000-00003.
2
Mivacurium chloride (BW B1090U)-induced neuromuscular blockade during nitrous oxide-isoflurane and nitrous oxide-narcotic anesthesia in adult surgical patients.在成年外科手术患者中,七氟醚-异氟醚麻醉和七氟醚-麻醉性镇痛药麻醉期间,氯化米库氯铵(BW B1090U)诱导的神经肌肉阻滞作用。
Anesth Analg. 1988 Jun;67(6):495-9.
3
Clinical pharmacology of mivacurium chloride (BW B1090U) in children during nitrous oxide-halothane and nitrous oxide-narcotic anesthesia.
Anesth Analg. 1989 Feb;68(2):116-21. doi: 10.1213/00000539-198902000-00009.
4
Neuromuscular and cardiovascular effects of mivacurium chloride in surgical patients receiving nitrous oxide-narcotic or nitrous oxide-isoflurane anaesthesia.
Can J Anaesth. 1989 Nov;36(6):641-50. doi: 10.1007/BF03005415.
5
The cardiovascular effects and histamine-releasing properties of 51W89 in patients receiving nitrous oxide/opioid/barbiturate anesthesia.51W89在接受氧化亚氮/阿片类药物/巴比妥类麻醉的患者中的心血管效应及组胺释放特性。
Anesthesiology. 1995 May;82(5):1131-8. doi: 10.1097/00000542-199505000-00007.
6
Neuromuscular and cardiovascular effects of mivacurium chloride (BW B1090U) during nitrous oxide-fentanyl-thiopentone and nitrous oxide-halothane anaesthesia.
Br J Anaesth. 1990 Feb;64(2):193-8. doi: 10.1093/bja/64.2.193.
7
Mivacurium-induced neuromuscular blockade following single bolus doses and with continuous infusion during either balanced or enflurane anesthesia.在平衡麻醉或安氟醚麻醉期间,单次推注剂量以及持续输注米库氯铵后所产生的神经肌肉阻滞作用。
Anesthesiology. 1989 Sep;71(3):362-6. doi: 10.1097/00000542-198909000-00008.
8
The clinical neuromuscular pharmacology of mivacurium chloride (BW B1090U). A short-acting nondepolarizing ester neuromuscular blocking drug.
Anesthesiology. 1988 May;68(5):723-32. doi: 10.1097/00000542-198805000-00010.
9
Comparison of the neuromuscular block induced by mivacurium, suxamethonium or atracurium during nitrous oxide-fentanyl anaesthesia.
Br J Anaesth. 1989 Oct;63(4):393-9. doi: 10.1093/bja/63.4.393.
10
Neuromuscular and cardiovascular effects of mivacurium chloride (BW B109OU) during nitrous oxide-narcotic, nitrous oxide-halothane and nitrous oxide-isoflurane anesthesia in surgical patients.手术患者在氧化亚氮-麻醉性镇痛药、氧化亚氮-氟烷和氧化亚氮-异氟烷麻醉期间,氯化米库氯铵(BW B109OU)对神经肌肉及心血管系统的影响。
Middle East J Anaesthesiol. 1990 Jun;10(5):469-78.

引用本文的文献

1
Caffeine Acts as an Agonist of Siglec-6, Inhibits MRGPRX2-Triggered Mast Cell Degranulation and Anaphylactoid Reactions.咖啡因作为唾液酸结合免疫球蛋白样凝集素-6的激动剂,抑制MRGPRX2触发的肥大细胞脱颗粒和类过敏反应。
Mediators Inflamm. 2025 Aug 30;2025:9580121. doi: 10.1155/mi/9580121. eCollection 2025.
2
Insights into Drug Cardiotoxicity from Biological and Chemical Data: The First Public Classifiers for FDA Drug-Induced Cardiotoxicity Rank.从生物学和化学数据中洞察药物的心脏毒性:美国食品和药物管理局药物致心脏毒性等级的首批公开分类器。
J Chem Inf Model. 2024 Feb 26;64(4):1172-1186. doi: 10.1021/acs.jcim.3c01834. Epub 2024 Feb 1.
3
Insights into Drug Cardiotoxicity from Biological and Chemical Data: The First Public Classifiers for FDA DICTrank.
从生物和化学数据洞察药物心脏毒性:美国食品药品监督管理局药物诱导心血管毒性排名的首个公开分类器
bioRxiv. 2023 Oct 18:2023.10.15.562398. doi: 10.1101/2023.10.15.562398.
4
MRGPRX2 and Adverse Drug Reactions.MRGPRX2 与药物不良反应。
Front Immunol. 2021 Aug 6;12:676354. doi: 10.3389/fimmu.2021.676354. eCollection 2021.
5
Hierarchical rule-based monitoring and fuzzy logic control for neuromuscular block.基于层次规则的神经肌肉阻滞监测与模糊逻辑控制
J Clin Monit Comput. 2000;16(8):583-92. doi: 10.1023/a:1012212516100.
6
Neuromuscular transmission and its pharmacological blockade. Part 2: Pharmacology of neuromuscular blocking agents.神经肌肉传递及其药理学阻断。第2部分:神经肌肉阻滞剂的药理学
Pharm World Sci. 1997 Feb;19(1):13-34. doi: 10.1023/a:1008641427473.
7
Early neuromuscular recovery characteristics following administration of mivacurium plus vecuronium.
Can J Anaesth. 1996 Apr;43(4):358-61. doi: 10.1007/BF03011714.
8
Neuroleptic malignant syndrome and mivacurium: a safe alternative to succinylcholine?抗精神病药恶性综合征与米库氯铵:琥珀酰胆碱的安全替代物?
Can J Anaesth. 1994 Sep;41(9):845-9. doi: 10.1007/BF03011591.
9
Adverse effects of nondepolarising neuromuscular blocking agents. Incidence, prevention and management.非去极化神经肌肉阻滞剂的不良反应。发生率、预防及处理
Drug Saf. 1994 Jun;10(6):420-38. doi: 10.2165/00002018-199410060-00002.
10
Succinylcholine.琥珀酰胆碱
Can J Anaesth. 1994 Jun;41(6):465-8. doi: 10.1007/BF03011538.